All children and adolescents with non-Hodgkin lymphoma from Germany, Austria, the Czech Republic and German-speaking Switzerland will be registered in the NHL-BFM Registry. The registry does not introduce any new therapies, but rather refers to the best currently available therapy based on the experience of previous studies and the literature. Inclusion in the registry also enables quality assurance through a second assessment by reference institutes and a co-assessment of the findings by the NHL-BFM study centre. Based on the experience of the study centre, individual advice can be given to the treating physicians in the form of a medical opinion.
All children and adolescents with non-Hodgkin lymphoma from Germany, Austria, the Czech Republic and German-speaking Switzerland will be registered in the NHL-BFM Registry . The registry does not introduce any new therapies, but rather refers to the best currently available therapy based on the experience of previous studies and the literature. Inclusion in the registry also enables quality assurance through a second assessment by reference institutes and a co-assessment of the findings by the NHL-BFM study centre. Based on the experience of the study centre, individual advice can be given to the treating physicians in the form of a medical opinion.
